STOCK TITAN

RELIEF THERAPEUTICS S/ADR - RLFTY STOCK NEWS

Welcome to our dedicated page for RELIEF THERAPEUTICS S/ADR news (Ticker: RLFTY), a resource for investors and traders seeking the latest updates and insights on RELIEF THERAPEUTICS S/ADR stock.

RELIEF THERAPEUTICS Holding SA (RLFTY) is a biopharmaceutical company dedicated to developing innovative treatment options for select specialty, unmet, and rare diseases. The company's mission is to provide therapeutic relief to patients through its portfolio of revenue-generating products, proprietary Physiomimic™ and TEHCLO™ platform technologies, and a clinical development pipeline focused on rare skin, metabolic, and respiratory disorders. With a team of experienced industry leaders, Relief Therapeutics aims to optimize patient outcomes and advance treatment paradigms. Headquartered in Geneva, the company is listed on the SIX Swiss Exchange and OTCQB in the U.S.

Rhea-AI Summary

Relief Therapeutics announced that its partner, NRx Pharmaceuticals, has filed for Breakthrough Therapy Designation with the FDA for aviptadil in patients with Critical COVID-19 who were also treated with remdesivir. The request is based on a post-hoc analysis of around 750 patients and aims to address ongoing respiratory failure. Relief's ongoing collaborations also include a licensing agreement with Acer Therapeutics for another treatment. The PDUFA date for Acer's new drug application is set for June 5, 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Acer Therapeutics (NASDAQ:ACER) and Relief Therapeutics (SIX:RLF, OTCQB:RLFTF, RLFTY) presented data on ACER-001 at the Society for Inherited Metabolic Disorders (SIMD) Annual Meeting held from April 10-13, 2022. The studies demonstrated that taste-masked sodium phenylbutyrate (ACER-001) is bioequivalent to BUPHENYL® under both fasting and fed conditions, with similar safety profiles. The FDA's PDUFA date for ACER-001 is set for June 5, 2022, with potential benefits for patients with urea cycle disorders (UCDs). The findings highlight ACER-001 as a promising alternative therapy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.8%
Tags
none
-
Rhea-AI Summary

RELIEF THERAPEUTICS Holding SA announced that the Swiss Patent Office has granted a patent for Vasoactive Intestinal Peptide (VIP) for treating drug-induced pneumonitis, enhancing the intellectual property for RLF-100 (aviptadil) until at least 2039. This patent covers treatment for checkpoint inhibitor-related pneumonitis and methotrexate-induced pneumonitis. Clinical studies, including the NIH-sponsored ACTIVE-3b/TESICO study, are ongoing. Aviptadil's inhalation method shows promising results, offering rapid and targeted treatment, which can improve patient outcomes significantly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

Relief Therapeutics Holding SA announced that the I-SPY COVID Trial involving its product aviptadil has been halted due to a lack of clinical benefit in critically ill COVID-19 patients. The Phase 2 trial, sponsored by Quantum Leap Healthcare Collaborative, aimed to evaluate potential agents that could improve recovery times. Relief's pipeline includes RLF-100 and a collaboration with Acer Therapeutics for ACER-001, with a new drug application accepted by the FDA. The future of aviptadil’s approval remains uncertain amid ongoing litigation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
covid-19
-
Rhea-AI Summary

Relief Therapeutics reported full-year 2021 results with a net loss of CHF 34.7 million, up from CHF 7.8 million in 2020. The company generated CHF 3.3 million in revenue from marketed products following the acquisition of APR Applied Pharma Research. Relief is positioned for potential growth with plans for U.S. commercialization of ACER-001, pending FDA approval by June 5, 2022. The company ended 2021 with a cash position of CHF 44.8 million, forecasting a cash runway into 2023. Notable acquisitions and product developments are set to enhance its commercial infrastructure.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.76%
Tags
none
-
Rhea-AI Summary

Relief Therapeutics' subsidiary, APR Applied Pharma Research, published promising in vivo data in the International Journal of Molecular Sciences. The study indicates that its PhysiomimicTM technology may provide prolonged release of amino acids (AAs), beneficial for managing phenylketonuria (PKU). Results show improved nitrogen balance, muscle mass, and strength in animal models. CEO Paolo Galfetti emphasized the potential of PKU GOLIKE(R), a product utilizing this technology, to mimic natural protein absorption. Relief aims for U.S. market entry of PKU GOLIKE(R) in 2022 while pursuing further clinical evidence.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

Relief Therapeutics announced that it has received a trademark registration for RLF-100 from the USPTO. This certification is significant as it strengthens the company’s intellectual property position for RLF-100, a drug in late-stage development targeting respiratory issues related to COVID-19 and other conditions. RLF-100 is a synthetic form of Vasoactive Intestinal Peptide with a proven history of safe use in several trials. The company aims to leverage this trademark to enhance its market position as it navigates ongoing clinical testing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.5%
Tags
none
-
Rhea-AI Summary

Relief Therapeutics has appointed Christopher Wick as the Senior Director, Head of U.S. Sales, to strengthen its U.S. expansion efforts. Wick, with over 20 years in pharmaceutical sales, previously led successful teams at Alexion Pharmaceuticals and held key roles at GlaxoSmithKline and Novartis. His experience will support the planned launch of pharmaceutical treatments, including ACER-001 for Urea Cycle Disorders, with a PDUFA date of June 5, 2022. The company aims to boost its U.S. market presence driven by its recent acquisitions and strategic collaborations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
Rhea-AI Summary

Relief Therapeutics announced the filing of Amendment No. 1 to its Registration Statement on Form 20-F with the SEC. This aims to register the company as a reporting entity under the Securities Exchange Act of 1934 and convert its Level 1 ADR program to Level 2, facilitating a future Nasdaq listing. However, there is no assurance that the registration will be effective or that the Nasdaq listing will occur. Notably, the filing does not involve any securities offering, hence no proceeds will be received from this ADR program.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

Relief Therapeutics has reported results from its clinical trial of Sentinox, a nasal spray intended for SARS-CoV-2 infected patients. Although the primary endpoint was not met due to a small sample size, a positive trend in efficacy was observed, with a near 90% viral load reduction in patients treated three times daily. Negativization rates were significantly higher in the treatment group at day six. Overall, Sentinox demonstrated a favorable safety profile, suggesting its potential as a therapeutic option against viral infections.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-25.02%
Tags

FAQ

What is the current stock price of RELIEF THERAPEUTICS S/ADR (RLFTY)?

The current stock price of RELIEF THERAPEUTICS S/ADR (RLFTY) is $4.8 as of December 19, 2024.

What is the market cap of RELIEF THERAPEUTICS S/ADR (RLFTY)?

The market cap of RELIEF THERAPEUTICS S/ADR (RLFTY) is approximately 58.3M.

What is the core focus of RELIEF THERAPEUTICS Holding SA?

RELIEF THERAPEUTICS focuses on developing innovative treatment options for select specialty, unmet, and rare diseases.

Where is RELIEF THERAPEUTICS headquartered?

RELIEF THERAPEUTICS is headquartered in Geneva with additional offices in Balerna, Switzerland, Offenbach am Main, Germany, and Monza, Italy.

What are the key areas of therapeutic focus for RELIEF THERAPEUTICS?

RELIEF THERAPEUTICS targets rare skin diseases, rare metabolic disorders, and rare respiratory diseases with its therapeutic portfolio.

What are the proprietary platform technologies of RELIEF THERAPEUTICS?

RELIEF THERAPEUTICS utilizes the globally patented Physiomimic™ and TEHCLO™ platform technologies in developing its treatment options for rare diseases.

Where is RELIEF THERAPEUTICS listed for trading?

RELIEF THERAPEUTICS is listed on the SIX Swiss Exchange under the symbol RLF and quoted on OTCQB in the U.S. under the symbols RLFTF and RLFTY.

Who leads the operational team at RELIEF THERAPEUTICS?

RELIEF THERAPEUTICS is led by an international team of experienced biopharma industry leaders with extensive research, development, and rare disease expertise.

What is the primary goal of RELIEF THERAPEUTICS?

RELIEF THERAPEUTICS aims to deliver improvements in efficacy, safety, and convenience to enhance patient outcomes and provide therapeutic relief to those suffering from rare diseases.

How does RELIEF THERAPEUTICS ensure balanced portfolio growth?

RELIEF THERAPEUTICS balances its portfolio with revenue-generating products, platform technologies, and a clinical development pipeline to drive sustainable growth and innovation.

What geographical presence does RELIEF THERAPEUTICS have?

RELIEF THERAPEUTICS has a strong presence in Geneva, Switzerland, along with offices in Balerna, Offenbach am Main, and Monza, reflecting its international focus.

How does RELIEF THERAPEUTICS approach corporate transparency?

RELIEF THERAPEUTICS maintains transparency by providing regular updates, engaging with shareholders, and aligning its strategic goals with the interests of various stakeholders to build trust and credibility.

RELIEF THERAPEUTICS S/ADR

OTC:RLFTY

RLFTY Rankings

RLFTY Stock Data

58.31M
Biotechnology
Healthcare
Link
United States of America
Geneva